Senior team members at RM Global have advised on and completed the following transactions and assignments:
Global Licensing Agreement Cardiovascular Device Platform
Advised Distal Access on the foregoing transaction
Series A Financing
Advised Distal Access on the foregoing transaction
Strategic Advisory Services
Advised Riverain Technologies on the foregoing transaction
Strategic Collaboration with Novartis to Screen & Develop Israel-Sourced Novel Drug Candidates
Advised BioLineRx on the foregoing transaction
Equity investment in Tria Beauty’s series D and Strategic Collaboration with Tria Beauty
Advised Amore Pacific on the foregoing transaction
Equity investment in Brickell Bio’s Series A and Strategic Collaboration with Brickell Bio
Advised Amore Pacific on the foregoing transaction
Equity investment in Neothetics (formerly “Lithera”) Series C and Strategic Collaboration with Neothetics
Advised Amore Pacific on the foregoing transaction
Strategic consulting & execution
Advised PacificPharma on the foregoing transaction
Equity financing
Advised U&I on the foregoing transaction
Equity Financing
Advised Bioamber on the foregoing transaction
Equity Financing
Advised Alereon on the foregoing transaction
Private Placement of Series B Financing Advice on business development & IPO
Advised Oscotec on the foregoing transaction